Novel Arylimidamides for Treatment of Visceral Leishmaniasis

Arylimidamides (AIAs) represent a new class of molecules that exhibit potent antileishmanial activity (50% inhibitory concentration [IC(50)], <1 μM) against both Leishmania donovani axenic amastigotes and intracellular Leishmania, the causative agent for human visceral leishmaniasis (VL). A syste...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Wang, Michael Zhuo, Zhu, Xiaohua, Srivastava, Anuradha, Liu, Qiang, Sweat, J. Mark, Pandharkar, Trupti, Stephens, Chad E., Riccio, Ed, Parman, Toufan, Munde, Manoj, Mandal, Swati, Madhubala, Rentala, Tidwell, Richard R., Wilson, W. David, Boykin, David W., Hall, James Edwin, Kyle, Dennis E., Werbovetz, Karl A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology (ASM) 2010
Assuntos:
Experimental Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2876428/
https://ncbi.nlm.nih.gov/pubmed/20368397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00250-10
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares